Modality
ERT
MOA
IL-17i
Target
RET
Pathway
Incretin
DravetCKDPV
Development Pipeline
Preclinical
Jan 2020
→ May 2030
PreclinicalCurrent
NCT03290166
1,418 pts·PV
2020-01→2030-05·Active
1,418 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-144.1y awayInterim· PV
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Active
Catalysts
Interim
2030-05-14 · 4.1y away
PV
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03290166 | Preclinical | PV | Active | 1418 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |